Capstone Holding Corp.
CAPSNasdaq
$0.26
↑ +0.2%Jul 17 close · end-of-day
Price
1Y↓ -82.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$51.6M
Net Income (TTM)
-$21.4M
Free Cash Flow (TTM)
-$5.1M
Gross Margin
24.1%
Operating Margin
-21.4%
Net Margin
-41.5%
ROE
-190.8%
ROIC
-36.4%
Debt / Equity
1.2
Net Cash
-$12.8M
Return 1Y
-84.1%
Company profile
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
- CEO
- Matthew E. Lipman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 38
- Headquarters
- Illinois
- Website
- www.capstonethx.com
Earnings
CAPS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$12.6M↑ +60.0%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $48.4M | $44.9M | $46.9M |
| Gross profit | $9.6M | $9.6M | $10.8M |
| Operating income | -$1.3M | -$638,000.00 | -$11.0M |
| Net income | -$3.8M | -$2.6M | -$21.2M |
| Diluted EPS | -$36.39 | -$34.87 | — |
| Operating cash flow | $1.6M | $3.8M | -$4.4M |
| Free cash flow | $1.4M | $3.7M | -$4.5M |
| Gross margin | 19.9% | 21.3% | 23.0% |
| Operating margin | -2.6% | -1.4% | -23.4% |
| Net margin | -7.9% | -5.7% | -45.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.9M | $12.3M | $10.3M | $7.9M | $12.9M | $13.7M | $12.5M | $12.6M |
| Gross profit | $2.8M | $3.0M | $2.1M | $1.3M | $3.1M | $3.3M | $3.1M | $3.0M |
| Operating income | $14,000.00 | $413,000.00 | -$348,000.00 | -$1.4M | -$260,000.00 | -$768,000.00 | -$8.5M | -$1.5M |
| Net income | -$381,000.00 | $34,000.00 | -$1.1M | -$1.7M | -$700,000.00 | -$2.0M | -$16.8M | -$1.9M |
| Diluted EPS | -$8.43 | -$6.33 | -$7.20 | -$0.47 | -$0.13 | -$0.35 | — | — |
| Operating cash flow | $107,000.00 | $2.2M | $2.7M | -$2.3M | -$1.7M | $0.00 | -$420,000.00 | -$2.8M |
| Free cash flow | $86,000.00 | $2.2M | $2.7M | -$2.3M | -$1.7M | $0.00 | -$540,000.00 | -$2.8M |
| Gross margin | 21.4% | 24.3% | 20.1% | 16.8% | 24.4% | 23.8% | 24.7% | 23.5% |
| Operating margin | 0.1% | 3.4% | -3.4% | -18.1% | -2.0% | -5.6% | -68.4% | -11.8% |
| Net margin | -3.0% | 0.3% | -10.7% | -21.9% | -5.4% | -14.8% | -134.6% | -15.2% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.